TScan Therapeutics, Inc. Common Stock

TCRXNASDAQUSD
0.32 USD
0.00 (0.22%)🟢PRE MARKET (AS OF 07:16 AM EDT)
🟢Market: OPEN

Shares of TScan Therapeutics, Inc. Common Stock (TCRX) are trading at $0.32. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 1/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics suggest TCRX is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Sep 15, 2026.

Open?$0.31
High?$0.33
Low?$0.31
Prev. Close?$0.32
Volume?12.8K
Avg. Volume?866.0K
VWAP?$0.32
Rel. Volume?0.01x
Bid / Ask
Bid?$0.26 × 100
Ask?$0.36 × 100
Spread?$0.11
Midpoint?$0.31
Valuation & Ratios
Market Cap?21.7M
Shares Out?63.5M
Float?50.6M
Float %?82.9%
P/E Ratio?N/A
P/B Ratio?0.31
EPS?-$1.74
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Employees
142
Market Cap
20.8M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2021-07-16
Address
830 WINTER STREET
WALTHAM, MA 02451
Phone: 857-399-9500
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bearish(-3/3)
Medium-Term (Wave)? Bearish(-2/3)
Short-Term (Ripple)? Neutral(0/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
0
Momentum?
50
Short Sent.?
38
Piotroski F-Score?1/9Weak
Altman Z-Score?-6.24Distress
Confidence?58%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?3.46%Low
Short Interest?1.7M
Days to Cover?7.0
Free Float50.6M
Avg Daily Volume251.0K
Settlement Date2026-08-31
Financial Health
Current Ratio?3.37Strong
Quick Ratio?3.37Strong
Cash Ratio?3.23Strong
Debt/Equity?0.47Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
92/100
P/E?
N/A
P/B?
Peers
100
S&P
97
0.31CHEAP
P/S?
Peers
100
S&P
50
3.05FAIR
P/FCF?
N/A
EV/EBITDA?
Peers
100
S&P
97
0.4CHEAP
EV/Sales?
S&P
97
-6.42CHEAP
Returns & Efficiency
ROE?
S&P
3
-170.6%WEAK
ROA?
S&P
3
-68.7%WEAK
Cash Flow & Enterprise
FCF?$-118439000
Enterprise Value?$-45687638
Fundamentals ratios updated end of day